The utility of intramuscular ziprasidone in the management of acute psychotic agitation

Annals of Clinical Psychiatry

Volumn 16, Issue 3, 2004, Pages 145-154

  Mendelowitz, Alan J ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

IM ziprasidone; Psychotic agitation; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

AGITATION; AKATHISIA; ARTICLE; ATAXIA; BIPOLAR DISORDER; BRADYCARDIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIZZINESS; DRUG CONTROL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DYSPHORIA; DYSTONIA; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; NAUSEA; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; RESPIRATION DEPRESSION; RESPIRATORY TRACT DISEASE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINUS BRADYCARDIA; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; HALOPERIDOL; HUMANS; INCIDENCE; INJECTIONS, INTRAMUSCULAR; LONG QT SYNDROME; LORAZEPAM; PIPERAZINES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; THIAZOLES;

EID: 4644245162     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1080/10401230490487025     Document Type: Article

References (35)

1. Asnis GM, Kaplan ML, Hundorfean G, Saeed W: Violence and homicidal behaviors in psychiatric disorders. Psychiatr Clin North Am 1997; 20:405-424.
2. Currier GW, Trenton A: Pharmacological treatment of psychotic agitation. CNS Drugs 2000; 16:219-228.
3. Zimbroff DL. Management of acute psychosis from emergency to stabilization. Available at: http://www. medscape.com/viewarticle/460109_5. Accessed December 12, 2003.
4. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: A novel antipsychotic agent with a unique receptor binding profile. Eur J Pharmacol 2001; 425:197-201.
5. Gunasekara NS, Spencer CM, Keating GM: Ziprasidone. A review of its use in schizophrenia and schizo-affective disorder. Drugs 2002; 62:1217-1251.
6. Geodon® [package insert]. New York, NY: Pfizer Inc; June 2002.
7. Miceli JJ, Wilner KD, Tensfeldt TG: Pharmacokinetics of intramuscular ziprasidone in healthy volunteers: Results from two controlled studies [poster]. Presented at the 154th Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, LA.
8. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacol 2001; 155:128-134.
9. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP: Intramuscular ziprasidone, 2mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62:12-18.
10. Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP: Validation of the behavioural activity rating scale (BARS)™: A novel measure of activity in agitated patients. J Psychiatr Res 2002; 36:87-95.
11. Brook S, Lucey JV, Gunn KP, for the Ziprasidone IM Study Group. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000; 61:933-941.
12. Swift RH, Harrigan EP, van Kamen DP: A comparison of fixed-dose intramuscular (IM) ziprasidone with flexible-dose IM haloperidol [poster]. Presented at the 151st Annual Meeting of the American Psychiatric Association; May 30-June 4, 1998; Toronto, Ontario, Canada.
13. Brook S, Walden J, Benettia I: Ziprasidone versus haloperidol in sequential IM/oral treatment of acute schizophrenia [poster]. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology; December 9-13, 2001; Waikoloa, Hawaii.
14. Pfizer Inc. FDA Psychopharmacological Drugs Advisory Committee: Briefing document for ziprasidone mesylate for intramuscular injection: 15 February 2001. New York, NY: Pfizer Inc.
15. Zimbroff DL, Brook S, Benattia I: Safety and tolerability of IM ziprasidone: Review of clinical trial data [poster]. Presented at the 155th Annual Meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, PA.
16. Daniel D, Brook S, Benattia I: Transition from IM to oral ziprasidone: Clinical efficacy and safety data [poster]. Presented at the 155th Annual Meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, PA.
17. max. Presented at the 155th Annual Meeting of the American Psychiatric Association; May 18-23, 2002, Philadelphia, PA.
18. Allen MH, Zimbroff DL, Jagoda AS: Treatment of acute agitation with atypical antipsyhotics 2003; 20. Available at: http://www.physweekly.com/ specialissue XX24.asp?issueid=73. Accessed December 13, 2003.
19. Clinton JE, Sterner S, Stelmachers Z, Ruiz E: Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med 1987; 16:319-322.
20. Citrome L: Current treatments of agitation and aggression. Available at: http://www.medscape.com/viewprogram/ 1866. Accessed December 12, 2003.
21. Citrome L: Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgrad Med 2002; 112:85-88, 94-6.
22. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52:177-180.
23. Foster S, Kessel J, Berman ME, Simpson GM: Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997; 12:175-179.
24. Hughes DH: Acute psychopharmacological management of the aggressive psychotic patient. Psychiatr Serv 1999; 50:1135-1137.
25. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15:335-340.
26. Bieniek SA, Ownby RL, Penalver A, Dominguez RA: A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998; 18:57-62.
27. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for ZYPREXA IntraMuscular (olanzapine for injection). February 14, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3685b1_01_lilly.pdf. Accessed December 15, 2003.
28. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158:1149-1151.
29. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E: Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs 2003; 63:493-512.
30. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21:389-397.
31. Wright P, Jewell H, Michell M, et al. A preliminary study of the safety, efficacy and pharmacokinetics of intramuscular olanzapine in patients with acute nonorganic psychosis [abstract]. Schizophren Res 1999; 36:318.
32. Wright P, Kiesler G, Michell M, et al. Safety and efficacy of intramuscular olanzapine in patients with acute nonorganic psychosis [abstract]. Schizophren Res. 1999; 36:318.
33. Currier GW, Simpson GM: Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62:153-157.
34. Russell JM, Mackell JA, Leaderer MC. Economic model of IM ziprasidone and IM haloperidol in acute agitation [poster]. Presented at the American Psychiatric Association 55th Institute on Psychiatric Services; October 29-November 2, 2003; Boston, MA.
35. Pondrom M, Ducate SE. Ziprasidone reduces pharmacy costs for correctional inpatients [poster]. Presented at the American Psychiatric Association 55th Institute on Psychiatric Services; October 29-November 2, 2003; Boston, MA.